Evidence map›Paper›PMID 39971488›Full record

ArticleHuman vaccines & immunotherapeutics2025

Vaccine effectiveness against influenza B/Victoria-associated medically attended influenza-like illness: Beijing, China, 2021-2022 influenza season.

Chunna Ma, Ying Sun, Li Zhang, Jiaojiao Zhang, Wei Duan, Jia Li, Jiaxin Ma, Lu Zhang, Yingying Wang, Daitao Zhang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chunna MaInstitute for Infectious Disease and Endemic Disease Control, Beijing Center for Disease Prevention and Control, Beijing, China.
Ying SunInstitute for Infectious Disease and Endemic Disease Control, Beijing Center for Disease Prevention and Control, Beijing, China.
Li ZhangInstitute for Infectious Disease and Endemic Disease Control, Beijing Center for Disease Prevention and Control, Beijing, China.
Jiaojiao ZhangInstitute for Infectious Disease and Endemic Disease Control, Beijing Center for Disease Prevention and Control, Beijing, China.
Wei DuanInstitute for Infectious Disease and Endemic Disease Control, Beijing Center for Disease Prevention and Control, Beijing, China.
Jia LiInstitute for Infectious Disease and Endemic Disease Control, Beijing Center for Disease Prevention and Control, Beijing, China.
Jiaxin MaInstitute for Infectious Disease and Endemic Disease Control, Beijing Center for Disease Prevention and Control, Beijing, China.
Lu ZhangInstitute for Infectious Disease and Endemic Disease Control, Beijing Center for Disease Prevention and Control, Beijing, China.
Yingying WangInstitute for Infectious Disease and Endemic Disease Control, Beijing Center for Disease Prevention and Control, Beijing, China.
Daitao ZhangInstitute for Infectious Disease and Endemic Disease Control, Beijing Center for Disease Prevention and Control, Beijing, China.
Quanyi WangInstitute for Infectious Disease and Endemic Disease Control, Beijing Center for Disease Prevention and Control, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Influenza B/Victoria viruses predominated during the 2021-2022 influenza season in Beijing, China, unlike most northern hemisphere countries, likely due to reduced international travel. We estimated influenza vaccine effectiveness (VE) against the B/Victoria lineage to provide a more comprehensive evaluation of 2021-2022 influenza VE. Between October 2021 and April 2022, patients aged ≥6 months with influenza-like illness (ILI) visiting outpatient departments in Beijing's influenza virological surveillance system were enrolled. A test-negative design was used to assess VE against influenza B/Victoria, adjusting for sex, age groups, the presence of chronic diseases, onset-to-enrollment interval, and symptom onset timing. Of the 8,813 eligible patients, 1,787 (20.3%) tested positive for influenza B/Victoria only. 573/8813 (6.5%) were vaccinated against influenza. The adjusted effectiveness against B/Victoria for all ages was 16.6% (95%

Indexed as

Influenza B virusInfluenza, HumanInfluenza VaccinesVaccine EfficacyAdolescentAdultAgedAged, 80 and overBeijingChildChild, PreschoolFemaleHumansInfantMaleMiddle AgedInfluenza VaccinesChinaInfluenzainfluenza-like illnesstest-negative designvaccine effectiveness

Identifiers

PMID39971488
PMCPMC11844929

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.